Mainz Biomed N.V. (QUCY)

Mar 13, 2026, 7:30 AM EDT - 3 days ago

Quantum Cyber (f/k/a Mainz Biomed) Announces Stock Ticker Symbol Change to NASDAQ: QUCY

Mar 11, 2026, 7:30 AM EDT - 5 days ago

Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors

Jan 14, 2026, 9:15 AM EST - 2 months ago

Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting

Nov 18, 2025, 8:01 AM EST - 4 months ago

Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America

Nov 12, 2025, 8:01 AM EST - 4 months ago

Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025

Nov 10, 2025, 8:01 AM EST - 4 months ago

Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)

Oct 8, 2025, 9:00 AM EDT - 5 months ago

Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Sep 2, 2025, 8:01 AM EDT - 6 months ago

Mainz Biomed Announces Registration of ColoAlert in the United Kingdom

Aug 13, 2025, 8:01 AM EDT - 7 months ago

Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®

Aug 4, 2025, 10:22 AM EDT - 8 months ago

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants

Jul 23, 2025, 8:01 AM EDT - 8 months ago

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

Jul 15, 2025, 8:01 AM EDT - 8 months ago

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition

Jun 25, 2025, 8:01 AM EDT - 9 months ago

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

Jun 10, 2025, 9:01 AM EDT - 9 months ago

Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

May 19, 2025, 8:01 PM EDT - 10 months ago

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants

May 16, 2025, 8:01 AM EDT - 10 months ago

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

Apr 29, 2025, 8:01 AM EDT - 11 months ago

Mainz Biomed Enters into Technology Partnership with EDX Medical Group

Apr 28, 2025, 8:01 AM EDT - 11 months ago

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval

Mar 27, 2025, 9:01 AM EDT - 1 year ago

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

Mar 13, 2025, 8:01 AM EDT - 1 year ago

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Mar 3, 2025, 8:01 AM EST - 1 year ago

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

Feb 20, 2025, 8:01 AM EST - 1 year ago

Mainz Biomed Expands into Switzerland with labor team w

Feb 11, 2025, 8:01 AM EST - 1 year ago

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

Jan 27, 2025, 8:01 AM EST - 1 year ago

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

Jan 21, 2025, 8:01 AM EST - 1 year ago

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

Dec 19, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Dec 16, 2024, 5:00 PM EST - 1 year ago

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

Dec 12, 2024, 8:00 PM EST - 1 year ago

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

Dec 3, 2024, 2:40 PM EST - 1 year ago

Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific

TMO

Nov 29, 2024, 8:45 AM EST - 1 year ago

Mainz Biomed Announces Stock Split

Oct 21, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Oct 8, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

Oct 1, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

Sep 18, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

Sep 4, 2024, 4:01 AM EDT - 1 year ago

Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert

Jul 25, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

Jul 9, 2024, 3:01 AM EDT - 1 year ago

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

Jul 2, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Provides Half Year 2024 Corporate Update

Jun 3, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

May 31, 2024, 5:01 PM EDT - 1 year ago

Mainz Biomed Reports Results of 2024 Annual General Meeting

May 28, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

May 20, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

May 7, 2024, 8:01 AM EDT - 2 years ago

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

Apr 25, 2024, 9:29 AM EDT - 2 years ago

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic

Apr 9, 2024, 8:01 AM EDT - 2 years ago

Mainz Biomed Reports Full Year 2023 Financial Results

Mar 19, 2024, 8:01 AM EDT - 2 years ago

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

Mar 18, 2024, 8:01 AM EDT - 2 years ago

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Mar 12, 2024, 8:01 AM EDT - 2 years ago

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Mar 5, 2024, 8:01 AM EST - 2 years ago

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Feb 27, 2024, 8:01 AM EST - 2 years ago

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community